Enzymes Market worth $23.74 billion by 2031- Exclusive Report by MarketsandMarkets™

MarketsandMarkets forecasts the global enzymes market will grow from $16.15 billion in 2026 to $23.74 billion by 2031, an 8.0% CAGR, driven by food processing, animal feed, biofuels, industrial biotechnology and sustainable manufacturing demand. Wastewater treatment is projected to be the fastest-growing application at a 9.2% CAGR, while South America is expected to lead regional growth at 9.1%. Industry consolidation includes Novonesis's €1.5 billion acquisition of dsm-firmenich's Feed Enzyme Alliance stake and Kerry's €150 million purchase of the NOLA lactase business.

Analysis

This is not a near-term demand signal; it is a low-quality market-sizing input that reinforces an existing distinction between pure-play enzyme exposure and diversified chemical/ingredients portfolios. NSIS.B has the clearest operating leverage because proprietary strains, regulatory dossiers, and customer formulation know-how create switching costs; incremental volume in feed, food processing, and industrial applications should carry materially higher contribution margins than at BAS or IFF. KRZ is a more targeted beneficiary in dairy-adjacent specialty applications, but its enzyme exposure is too small to change group earnings without evidence of cross-selling or pricing traction.

The important second-order effect is consolidation: NSIS.B's vertically integrated feed position may convert a formerly shared channel into superior customer-data access and distribution economics. That could pressure smaller specialty suppliers and reduce dsm-firmenich's strategic optionality in animal nutrition, even if DSFIR retains broader nutrition and health capabilities. Conversely, rising enzyme penetration can be deflationary for customers' unit processing costs, making food manufacturers and ethanol/feed producers reluctant to substitute suppliers during a weak macro cycle—supporting pricing resilience for the formulation owner.

Over 1-3 months, catalyst quality rests on FY27 organic-growth guidance, price-versus-volume disclosure, capacity-utilization trends, and whether the feed integration produces sales-force synergies rather than channel disruption. Over 6-18 months, the thesis requires premium applications to outgrow commodity carbohydrases; otherwise, industry growth can be captured through price competition and dilute returns on fermentation capacity. Falsify a relative-long NSIS.B thesis if organic growth falls below mid-single digits for two quarters, gross margin contracts despite mix claims, or feed integration costs/guidance rise materially.

Contrarian view: consensus may already award NSIS.B a scarcity premium for biologics growth, while broad enzyme-market growth alone does not justify further multiple expansion. The better risk-adjusted expression is relative value rather than a directional sector bet: the market is sufficiently fragmented that share gains and execution, not category CAGR, will determine earnings dispersion.

Key Decisions for Investors

• Maintain a 6-12 month long NSIS.B / short DSFIR pair, sized beta-neutral: NSIS.B has superior feed-enzyme integration upside while DSFIR has less direct participation in that profit pool. Target 10-15% relative return; exit if NSIS.B organic growth underperforms DSFIR by more than 300 bps over two reported quarters or integration guidance deteriorates.
• Add KRZ only on a 8-10% pullback or after results demonstrate specialty-enzyme revenue acceleration and stable segment margin; use a 12-month horizon. Upside depends on cross-selling into dairy and reduced-sugar formulations, but lack of segment disclosure is a reason to keep position size small rather than chase the theme.
• Do not add broad long exposure to IFF, BAS, or ABF on this information alone. Their enzyme sensitivity is diluted by larger businesses and the relevant earnings catalysts are portfolio actions, input costs, and end-market volumes—not a third-party category forecast.
• Set an earnings watch for NSIS.B: price/mix, feed sales retention, integration costs, and fermentation-capacity capex. Upgrade the long only if management demonstrates mid-single-digit-plus organic growth with stable-to-expanding gross margin; reduce if growth is purchased through discounting or capex intensity rises without volume conversion.